Market Closed -
Nasdaq
01:30:00 23/05/2024 am IST
5-day change
1st Jan Change
983.8
USD
-1.02%
+0.57%
+12.01%
This article is reserved for members
Not a member ?
Free registration
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing
23/05
MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
21/05
MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115
21/05
MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25
20/05
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing
18/05
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing
18/05
MT
Sector Update: Health Care Stocks Mixed Late Afternoon
18/05
MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060
18/05
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing
16/05
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
14/05
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
13/05
DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review
13/05
MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent
13/05
CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
08/05
CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
07/05
MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept
03/05
MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
03/05
MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177
03/05
MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016
02/05
MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189
02/05
MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...
02/05
Sector Update: Health Care Stocks Mixed Premarket Thursday
02/05
MT
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
02/05
Regeneron: Adjusted EPS down 4% in Q1
02/05
CF
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off
02/05
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
983.8
USD
Average target price
1,042
USD
Spread / Average Target
+5.91%
Consensus
1st Jan change
Capi.
+12.01% 107B +9.99% 114B -3.07% 22.22B -0.67% 21.28B -4.64% 18.8B -6.90% 17.51B -39.36% 17.17B +5.82% 14.14B +33.05% 12.2B +13.63% 8.01B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1